hamburger-icon CORPORATE GOVERNANCE CORPORATE GOVERNANCE STATEMENT Investors At a Glance Financial Highlights Investment Case CEO Q&A Share Tools Results, Reports and Presentations Financial Calendar Regulatory News Shareholder Services Corporate Governance Corporate Governance Statement Board of Directors Tax Strategy AIM Rule 26 Investor Contacts Sustainability Newsroom As a company whose shares are traded on AIM, the Company is subject to the AIM Rules (the ‘AIM Rules’) for Companies. Pursuant to (amended) AIM Rule 26, every company whose shares are traded on AIM is required to state on its website which corporate governance code it applies, how it complies with that code, and where it departs from its chosen corporate governance code an explanation of the reasons for doing so (Corporate Governance Statement). The Board has elected to report against the UK Corporate Governance Code as we believe that it encompasses the best practice in UK governance. At its heart, the Code emphasises the value of good corporate governance to long-term sustainable success and this fits with our own corporate ethos. Although AIM listed companies are not required to comply with the Code (unlike those with a premium listing on the Main Market), the Board’s election to follow it underpins our belief that effective corporate governance assists the delivery of the Group’s corporate strategy, the management of risk and the generation of shareholder value. Good governance improves Board efficiency, boosts investor confidence, reduces cost of capital and helps protect our shareholders’ long-term interests. Clinigen values corporate governance highly, not only in the boardroom but across the whole business of the Group. Whilst the Clinigen Board follows both the Code and AIM Rules when ensuring that the highest standards of governance are met, we are also influenced by our corporate culture and our Company purpose. Our culture, which encompasses the values of excellence, teamwork, putting patients first, ethics and integrity is known internally as the ‘Clinigen Way’ as referenced in the ESG section on page 32 of the Annual Report. Our Company purpose of ‘Right Medicine, Right Patient, Right Time’ is set out in our Strategic Report on pages 8 to 11. The following section outlines in broad terms how the Board has managed and applied standards of corporate governance that are appropriate for the Group’s size and circumstances Board Leadership and Company Purpose Board activities and the governance, culture and mission influences Board committees Board and committee meetings Division of Responsibilities Board Composition, succession and evaluation Nomination Committee Report Board Changes Remuneration Committee Risk Management and Internal Control Communicating with Investors Share Dealing AGM Whistleblowing Schedule of Matters Roles of Senior Board Members RELATED LINKS ANNUAL REPORT ANNUAL REPORT 2021 Download report (pdf 4.64mb) INVESTORS INVESTMENT CASE Read more SHARE TOOLS SHARE TOOLS View all OUR GLOBAL OFFICES United Kingdom Europe Asia, Pacific and Japan South Africa United States SITE TOOLS Stay In Touch Cookie settings FIND A MEDICINE Online services for healthcare professionals Hard to find medicines (Clinigen Direct) Managed Access Programs (Cliniport) Clinigen Products Twitter Linkedin © Copyright 2021 Clinigen Group plc. By Emperor OUR USE OF COOKIES We use cookies to improve your experience. By clicking accept, we will set recommended analytics cookies. AcceptRejectSettings